Cardio Diagnostics Holdings, Inc., a precision cardiovascular medicine company trading on NASDAQ under the symbol CDIO, has engaged IBN to support its corporate communications strategy. The company focuses on developing blood-based solutions for preventing and detecting cardiovascular disease by integrating epigenetics, genetics, and artificial intelligence. This partnership aims to enhance the visibility of Cardio Diagnostics' clinical tests and data platforms, which are designed to provide patient-specific insights into cardiovascular health.
The company's product portfolio includes Epi+Gen CHD™, a prescription-only test that assesses an individual's three-year risk of coronary heart disease. Other offerings are PrecisionCHD™ for detection and management, HeartRisk™ for population-level intelligence, and CardioInnovate360™ to support cardiovascular therapy development. These tools leverage a proprietary AI-driven Integrated Genetic-Epigenetic Engine, known as the Core Technology, to make cardiovascular disease prevention, detection, and management more accessible and precise.
By engaging IBN, Cardio Diagnostics seeks to leverage a specialized communications platform that focuses on the biotechnology and biomedical sectors. IBN is part of a dynamic brand portfolio that includes over 75 brands, providing services such as wire solutions, article syndication to more than 5,000 outlets, enhanced press release distribution, and social media outreach to millions of followers. This collaboration is intended to help Cardio Diagnostics reach a broader audience of investors, journalists, and the public, thereby supporting its mission to become a leading medical technology company in cardiovascular disease care.
The move underscores the growing importance of effective corporate communications in the healthcare technology sector, particularly for companies developing innovative diagnostic tools. Cardio Diagnostics' approach combines molecular biomarkers with AI to generate personalized insights, which could potentially transform how cardiovascular diseases are managed. For more information on the company's latest developments, updates are available in its newsroom at https://ibn.fm/CDIO. This engagement with IBN highlights Cardio Diagnostics' commitment to advancing its technologies and expanding its impact in the precision medicine landscape.
